International Clinics
Daily
EMA recommends daraxonrasib for metastatic pancreatic cancer after a fast-tracked phased review
On 15 October 2026 the EMA recommended authorising Rasonque (daraxonrasib) for metastatic pancreatic adenocarcinoma.